Boehringer Ingelheim Bullish In Oncology Despite Olmutinib U-Turn

Boehringer Ingelheim culled its late-stage lung cancer partnership with Hanmi after spending $65m in the first year because of the rapidly changing environment in the EGFR-positive lung cancer space. The German company doesn't intend to sit around licking its olmutinib-induced wounds, though, and is still committed to the lung cancer space.

LungCancerCells_1200x675
• Source: Shutterstock

Boehringer Ingelheim GMBH's Jörg Barth, corporate senior vice president, therapeutic area head, oncology, says that lung cancer is still a key focus of investment for the company "because of the huge unmet need". He was speaking to Scrip after the company revealed that it was pulling out of its partnership with Hanmi Pharmaceutical Co. Ltd. for the Phase III third-generation EGFR inhibitor olmutinib. Despite the loss of its major late-stage oncology hope, the firm is emphasizing its other opportunities to take new advances in lung cancer to market.

Doubts over olmutinib's ability to compete in a fast-moving space occupied by strong on-market and pipeline rivals had been expressed by observers since the deal was signed in July 2015

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas